Next Article in Journal
And If the Discovery of New Drugs for the Treatment of Brain Diseases Depends on Asian Countries?
Previous Article in Journal
Drug Reformulations and Repositioning in the Pharmaceutical Industry and Their Impact on Market Access: Regulatory Implications
 
 
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Are Payers Treating Orphan Drugs Differently?

Tufts Center for the Study of Drug Development, 75 Kneeland Street, Suite 1100, Boston, MA 02111, USA
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2014, 2(1), 23513; https://0-doi-org.brum.beds.ac.uk/10.3402/jmahp.v2.23513
Submission received: 5 December 2013 / Revised: 5 December 2013 / Accepted: 5 December 2013 / Published: 15 January 2014

Abstract

Background: Some orphan drugs can cost hundreds of thousands of dollars annually per patient. As a result, payer sensitivity to the cost of orphan drugs is rising, particularly in light of increased numbers of new launches in recent years. In this article, we examine payer coverage in the United States, England and Wales, and the Netherlands of outpatient orphan drugs approved between 1983 and 2012, as well as the 11 most expensive orphan drugs. Methods: We collected data from drug regulatory agencies as well as payers and drug evaluation authorities. Results: We found that orphan drugs have more coverage restrictions than non-orphan drugs in all three jurisdictions. From an economic perspective, the fact that a drug is an orphan product or has a high per-unit price per se should not imply a special kind of evaluation by payers, or necessarily the imposition of more coverage restrictions. Conclusion: Payers should consider the same set of decision criteria that they do with respect to non-orphan drugs: disease severity, availability of treatment alternatives, level of unmet medical need, and cost-effectiveness, criteria that justifiably may be taken into account and traded off against one another in prescribing and reimbursement decisions for orphan drugs.
Keywords: orphan drugs; reimbursement; pricing orphan drugs; reimbursement; pricing

Share and Cite

MDPI and ACS Style

Cohen, J.P.; Felix, A. Are Payers Treating Orphan Drugs Differently? J. Mark. Access Health Policy 2014, 2, 23513. https://0-doi-org.brum.beds.ac.uk/10.3402/jmahp.v2.23513

AMA Style

Cohen JP, Felix A. Are Payers Treating Orphan Drugs Differently? Journal of Market Access & Health Policy. 2014; 2(1):23513. https://0-doi-org.brum.beds.ac.uk/10.3402/jmahp.v2.23513

Chicago/Turabian Style

Cohen, Joshua P., and Abigail Felix. 2014. "Are Payers Treating Orphan Drugs Differently?" Journal of Market Access & Health Policy 2, no. 1: 23513. https://0-doi-org.brum.beds.ac.uk/10.3402/jmahp.v2.23513

Article Metrics

Back to TopTop